

Long-term Outcomes and Safety of Radical Transmediastinal Esophagectomy with Preoperative Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Thoracic Esophagus

Yukinori Yamagata (✉ yuyamaga-ty@umin.ac.jp)

National Cancer Center Hospital <https://orcid.org/0000-0003-2624-1251>

Kazuyuki Saito

Dokkyo Ika Daigaku Saitama Iryo Center

Kosuke Hirano

Dokkyo Ika Daigaku Saitama Iryo Center

Masatoshi Oya

Dokkyo Ika Daigaku Saitama Iryo Center

Research

Keywords: ESCC; esophageal squamous cell carcinoma, TME; transmediastinal esophagectomy, NAC; neoadjuvant chemotherapy, DCF therapy; docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy

Posted Date: July 8th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-40568/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on September 22nd, 2020. See the published version at <https://doi.org/10.1186/s12957-020-02023-2>.

Abstract

Background

It is unknown whether transmediastinal esophagectomy (TME) is an acceptable surgical procedure for locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we investigated the feasibility of and long-term survival after TME with neoadjuvant docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy (DCF therapy).

Methods

This retrospective, observational study included locally advanced resectable ESCC. All patients received two cycles of preoperative DCF therapy (60 mg/m² of docetaxel and cisplatin on day 1 and 700 mg/m²/day of 5-FU on days 1-5 in each cycle) followed by radical TME. The main outcomes were survival and the rate of adverse events of chemotherapy and surgery.

Results

Sixteen patients were included in this study. All patients received two cycles of DCF therapy, followed by surgery. The median follow-up duration of the 16 patients was 35.4 months. The 2-year overall survival (OS) was 93.3% (95% confidence interval [CI], 61.3-99.0), and the 3-year OS was 78.8% (95% CI, 47.3-92.7). The 2-year and 3-year relapse-free survivals were both 73.3% (95% CI, 43.6-89.1). Leucopenia and neutropenia occurred in most patients; however, they were controllable. Fifteen patients completed TME and one was converted to open transthoracic esophagectomy because of tracheal injury. Three-field dissection was performed for 12 of 16 patients (75%), and R0 resection was achieved in 15 of 16 patients (93.8%). Three cases of Grade IIIb chylothorax were observed. There was no mortality in this study.

Conclusion

Combined neoadjuvant DCF and TME for locally advanced ESCC was safe and less invasive than traditional therapies and had a satisfactory long-term prognosis.

Introduction

Esophageal cancer is known to have aggressive metastatic potential with poor prognosis¹. Additionally, even in relatively early stages of esophageal cancer, lymph node metastases can occur because of rich lymphatic flow in the esophagus².

Radical esophagectomy remains the standard treatment for resectable esophageal cancer¹. To control widespread lymph node metastasis, esophagectomy with cervical to abdominal lymph node dissection, so-called three-field dissection (3FD), has been performed for thoracic esophagus cancer in Japan³. However, esophagectomy alone is not sufficient to improve prognosis. Multidisciplinary treatment, i.e. chemotherapy and/or radiotherapy added to surgery, is effective. In Western countries, preoperative neoadjuvant chemoradiotherapy (NACRT) is popular².

In contrast, preoperative neoadjuvant chemotherapy (NAC) is the standard therapy in Japan because of the results of the JCOG9907 study⁴. The prognosis of esophageal cancer has improved with multidisciplinary treatment. However, it remains unsatisfactory.

There are two possible ways to further improve the prognosis of esophageal cancer. One is to strengthen preoperative treatment, and the other is to improve the surgical procedure. Combination NAC of 5-fluorouracil (5-FU) and cisplatin (CF therapy) is the standard treatment for locally advanced esophageal cancer in Japan⁴. To strengthen this treatment, we

introduced triplet chemotherapy, namely, docetaxel, cisplatin, and 5-FU combination chemotherapy (DCF therapy). To improve surgical outcomes, we focused on the approach of esophagectomy. Conventionally, a transthoracic approach to the thoracic esophagus is needed for 3FD. However, transthoracic esophagectomy (TTE) has a high rate of respiratory complications⁵, despite thoroscopic surgery becoming widespread^{6,7}. Furthermore, the presence of respiratory complications exacerbates the prognosis after esophagectomy⁸⁻¹⁰. Esophagectomy using the transmediastinal approach (non-transthoracic approach) has fewer respiratory complications than TTE¹¹. However, radical lymphadenectomy by transmediastinal esophagectomy (TME) is difficult. TME was initially performed as an esophageal extraction¹², and mediastinoscopy was introduced in the 1990s^{13,14}. Mediastinal dissection under inflatable mediastinoscopy was then developed, and complete mediastinal dissection without thoracotomy has become possible in recent years^{15,16}.

We first performed TME using an inflatable mediastinoscope in June 2015 and have performed 20 radical esophagectomies for thoracic or junctional esophageal squamous cell carcinoma (ESCC) and adenocarcinoma. In 16 of those 20 cases, which were estimated as clinical stage II to IVa ESCC, we added two cycles of preoperative DCF therapy as NAC. In this report, we evaluated the safety of this therapy and the long-term survival of this cohort.

Methods

This was a retrospective, observational study. Written informed consent was required from all patients before the start of therapy. We reviewed general information of the patients, histopathological characteristics of the tumours, and data concerning treatment and follow-up. This study was approved by the ethics committee of Dokkyo Medical University Saitama Medical Center (No. 1679).

Patients

This study included 16 patients with resectable locally advanced ESCC. All patients received two cycles of preoperative DCF therapy followed by radical TME from June 2015 to October 2017.

Preoperative chemotherapy

DCF therapy was repeated twice every 4 weeks as preoperative chemotherapy. A dose of 60 mg/m² docetaxel and cisplatin was administered by drip infusion on day 1, and 700 mg/m²/day 5-FU was administered by continuous infusion on days 1–5. The dose was appropriately adjusted according to the performance status, renal function, and adverse events (AEs) in the first cycle.

Surgical procedure

All patients underwent radical TME with regional lymphadenectomy using mediastinoscopy and laparoscopy.

First, upper to middle mediastinal dissection was performed using a 4-cm left cervical incision under single-port (GelPOINT®Mini, Applied Medical Co., Ltd, Rancho Santa Margarita, CA, USA) inflatable mediastinoscopy (Fig. 1-a). From the left neck, we dissected the upper and middle mediastinal lymph nodes, including the lymph nodes around the left recurrent laryngeal nerve, carina, and bilateral main bronchi (Fig. 2). Subsequently, a stomach tube was constructed, and dissection around the celiac axis was performed under laparoscopy (Fig. 1-b). Next, transhiatal lower mediastinal dissection was performed using a mediastinoscope from the esophageal hiatus. Finally, we extended the left cervical incision to the right side (Fig. 1-c) and performed cervical dissection in the direct view; 3FD was then completed. We usually selected stomach tube reconstruction with a mediastinal route, and esophago-stomach tube anastomosis was performed by a circular stapler in the neck.

Statistical analysis

Overall survival (OS) was measured from the date of the start of chemotherapy to the date of death or last follow-up. Relapse-free survival (RFS) was measured from the date of the start of chemotherapy to the date of the first evidence of tumour recurrence. Relapse-free patients were censored at the date when the absence of relapse was confirmed. OS and RFS were calculated by the Kaplan-Meier method. All statistical analyses were performed by the freely available software EZR version 1.37¹⁷.

The clinical and pathological staging of the tumours were classified according to the tumour-node-metastasis classification of the Union for International Cancer Control, eighth edition¹⁸. Pathological response of chemotherapy was classified according to the Japanese Classification of Esophageal Cancer, eleventh edition¹⁹. AEs during chemotherapy were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0²⁰. Postoperative complications were described according to the Clavien-Dindo classification, version 2.0²¹.

Results

Patient characteristics

Sixteen patients with ESCC were included. All patients were diagnosed as having clinical stage II to IVa disease. For these 16 patients, two cycles of DCF therapy were administered, followed by radical TME. The characteristics of the patients are summarized in Table 1.

Table 1
Characteristics
of patients in
this cohort

Chemotherapy and adverse events

Although 6 of 16 patients (37.5%) received a reduced dose of chemotherapy because of low-performance status, low renal function, or occurrence of AEs, all 16 patients completed two cycles of DCF therapy. Therefore, safety analysis was performed in all patients. AEs during chemotherapy are shown in Table 2. Leucopenia and neutropenia occurred in most of the patients; however, they were controllable. Other than leucopenia and neutropenia, Grade ≥ 4 AEs were not observed. There was no mortality during chemotherapy.

Table 2
Adverse
events during
chemotherapy

Surgical treatment

All 16 patients were scheduled for TME. Fifteen successfully completed TME, but 1 was converted to open TTE because of intraoperative tracheal injury. 3FD was performed in 12 of 16 patients (75%), and R0 resection was achieved in 15 of 16 patients (93.8%). The median postoperative hospital stay was 16 days. Surgical findings are summarized in Table 3.

Table 3
Surgical
findings

Operative morbidity and mortality

The median operation time was 489 minutes, and the median intraoperative blood loss was 180 mL. The only intraoperative complication was one case of tracheal injury. Postoperative complications are shown in Table 4. Grade IIIb chylothorax was observed in three patients, and re-operation was required in these patients. Grade IIIa recurrent nerve paralysis was observed in one patient. Anastomotic leakage was not observed; however, as a late complication after discharge, anastomotic stricture was observed in six patients. There was no surgical mortality.

Table 4
Postoperative
complications

Pathological findings and response to chemotherapy

The pathological findings are shown in Table 5. A complete pathological response to preoperative chemotherapy (Grade 3) was observed in two patients, and partial response (Grade 1b and 2) was observed in seven patients; therefore, the pathological complete response rate was 12.5% (2/16), and the pathological response rate was 56.3% (9/16).

Table 5
Pathological
findings

Overall and relapse-free survival

The OS and RFS curves are shown in Fig. 3. The median follow-up of the 16 patients was 35.4 months. The 2-year OS was 93.3% (95% confidence interval [CI], 61.3–99.0), and the 3-year OS was 78.8% (95% CI, 47.3–92.7). The 2-year and 3-year RFS were both 73.3% (95% CI, 43.6–89.1). Three patients died during follow-up; two died of tumour recurrence, and one died of secondary-induced acute myeloid leukaemia.

Discussion

This is the first report of long-term survival of patients undergoing TME with NAC for locally advanced ESCC. Our study demonstrated that the combination of preoperative DCF therapy and TME for thoracic ESCC could be performed safely and might lead to better prognosis than the current standard treatments. In the JCOG9907 trial, which assessed NAC for ESCC, the 3-year OS was 62%, and the 5-year OS was 55%; these are the highest survival rates observed among similar randomized controlled trials (RCTs)^{2, 4, 22}. The study by Natsugoe et al, which was an RCT assessing NACRT, had a 3-year OS of 57%; this is the highest survival among RCTs assessing NACRT^{2, 22, 23}. Conversely, our study showed a 3-year OS of 78.8%. Although it is difficult to compare our results with those of RCTs because our study was a retrospective observational study, our results seemed to be as good or better than those of these RCTs. There are two possible reasons for this discrepancy: 1) the superiority of DCF therapy and 2) the curability and low invasiveness of the TME procedure.

Neoadjuvant DCF therapy in our study demonstrated relatively high toxicity; however, it had a remarkable tumour control effect, with 12.5% (2/16) of patients having complete response and 56.3% (9/16) having pathological response. In the JCOG9907 trial, the complete response rate of NAC (CF therapy) was 2.4%, and the clinical response rate was 38%⁴. Therefore, triplet DCF therapy seems to be more effective than doublet CF therapy. Hara et al reported a phase II study on preoperative DCF therapy and found good results, with 17.1% (7/41) achieving a Grade 3 response and 34.1% (14/41) achieving a Grade 2 response²⁴. Therefore, they saw greater effectiveness of DCF than we did. However, in their study, DCF therapy consisted of docetaxel and cisplatin at 70 mg/m² on day 1 and 5-FU at 750 mg/m²/day on days 1–5 repeated three times every 3 weeks, so their patients received a higher cumulative dose than those in our study²⁴. In Natsugoe's study, NACRT consisted of 40 Gy of radiation and CF therapy (cisplatin: 7 mg over 2 h and 5-FU: 350 mg over 24 h during radiotherapy), and in the NACRT arm, 13.6% (3/22) of patients had a Grade 3 response and 31.8% (7/22) had a Grade 2 response²³. Therefore, we conclude that neoadjuvant triplet chemotherapy is superior to doublet chemotherapy

and comparable to CRT in terms of patient response. In Japan, the JCOG1109 trial, which is a triple-arm RCT comparing CF versus DCF versus radiotherapy with CF as preoperative therapy, is now ongoing²⁵.

In terms of AEs, DCF therapy showed a higher rate of Grade 3/4 toxicities than what has been previously observed with CF therapy or CRT, especially in hematological components (leucopenia and neutropenia)^{4, 23, 24}. However, leucopenia and neutropenia were manageable, and neither our study nor Hara's phase II study had any chemotherapy-related death²⁴. Therefore, neoadjuvant triplet chemotherapy seems to be safe. Although the DCF therapy in Hara's study had a higher dose than ours, there was no difference in the extent of AEs between these two studies²³. Hence, we might have been able to introduce more powerful DCF therapy.

As we mentioned in the introduction, the standard treatment for locally advanced ESCC in Japan is esophagectomy with 3FD, and it is believed that 3FD requires TTE. Therefore, TTE was performed for esophagectomy in the JCOG9907 trial, and Hara's study (Natsugoe's study also suggested that TTE was performed; however, details were not provided)^{4, 23, 24}. In contrast, we performed TME with 3FD in this study. TME does not require thoracotomy and therefore is associated with fewer respiratory complications than TTE¹¹. Infectious complications, including respiratory complications, may be directly linked to prognosis after esophageal cancer surgery^{8, 9}; this was shown in the exploratory analysis of JCOG9907¹⁰. In our study, we observed only two cases of pneumonia as infectious complications, and this result might have led to a better prognosis.

Some argue that TME is less radical than TTE. Previously, it was difficult to dissect the mediastinal lymph nodes, especially the nodes around the left recurrent laryngeal nerve or carina, without a transthoracic approach. However, the development of videoscopy and surgical devices has enabled mediastinal dissection without a transthoracic approach^{15, 16}. We performed upper to middle mediastinal dissection under single-port inflatable mediastinoscopy from the left neck. We dissected 57.5 lymph nodes per operation and could radically dissect lymph nodes around the left recurrent laryngeal nerve, carina, and bilateral main bronchi (Fig. 2). This less invasive procedure may be beneficial to patient prognosis. In Hara's study, the 2-year progression-free survival was 74.5%, and the 2-year OS was 88.0%²⁴; in contrast, in our study, the 2-year RFS was 73.3%, and the 2-year OS was 93.3%. Even though a higher dose of DCF therapy was administered in Hara's study²⁴, our study had comparable results. This might indicate the superiority and radicality of our TME procedure, despite its less invasive nature.

However, our procedure was not without complications. We had three cases of chylothorax that required re-operation. All three cases could be controlled by laparoscopic transhiatal thoracic duct ligation, and patients recovered quickly²⁶. Our TME procedure usually preserved the thoracic duct; however, highly advanced tumours would have required ligation or excision of the thoracic duct. Another complication was anastomotic stricture. We did not observe anastomotic leakage during treatment; however, six cases of anastomotic stricture requiring balloon dilation were observed after discharge. We used a circular stapler for esophagogastric tube anastomosis; it might have been possible to reduce anastomotic stricture by using a linear stapler or hand-sewing.

Combined neoadjuvant DCF and radical esophagectomy under TME showed fairly good results; however, this was a single-center, retrospective study in a small number of patients. To truly demonstrate the usefulness of our treatment, it is necessary to perform RCTs to verify both the superiority of neoadjuvant DCF and the superiority of TME to TTE.

Regarding neoadjuvant DCF, as we mentioned above, the JCOG1109 trial, which compares doublet chemotherapy, triplet chemotherapy, and chemoradiotherapy, is currently ongoing. Therefore, our future direction should be to promote an RCT comparing the superiority of TME to TTE for resectable locally advanced esophageal cancer.

Conclusion

Despite some complications, our combination therapy of neoadjuvant DCF and TME for locally advanced ESCC had a satisfactory long-term prognosis with no treatment-related mortality. These results suggest that triplet DCF might be safe and more effective than doublet CF or CRT as neoadjuvant therapy, and TME might be less invasive than TTE while providing treatment that is as radical.

Declarations

Ethics approval and consent to participate section

This study was approved by the ethics committee of Dokkyo Medical University Saitama Medical Center (No. 1679).

Consent for publication

Written informed consent was required from all patients before the start of therapy. Copies of the written consent are available for review by the Editor-in-Chief of the journal.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding authors on reasonable request.

Competing interests

The authors declare no conflict of interest.

Funding

There was no fundamental support in this study.

Authors' contributions

YY, KS and KH contributed to the data analysis, manuscript editing, article revision, and data supplement. All authors read and approved the final manuscript, and agreed to be accountable for all aspects of the work.

Acknowledgements

None.

References

1. Tomaszek S, Cassivi SD. Esophagectomy for the treatment of esophageal cancer. *Gastroenterol Clin North Am* 2009; **38**: 169–181, x.
2. Matsuda S, Takeuchi H, Kawakubo H, Ando N, Kitagawa Y. Current advancement in multidisciplinary treatment for resectable cStage II/III esophageal squamous cell carcinoma in Japan. *Ann Thorac Cardiovasc Surg*. 2016;22:275–83.
3. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. *Oncology* 1991; 48: 411–420.
4. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). *Ann Surg Oncol*. 2012;19:68–74.

5. Takeuchi H, Miyata H, Gotoh M, Kitagawa Y, Baba H, Kimura W, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. *Ann Surg*. 2014;260:259–66.
6. Seesing MFJ, Gisbertz SS, Goense L, van Hillegersberg R, Kroon HM, Lagarde SM, et al. A propensity score matched analysis of open versus minimally invasive transthoracic esophagectomy in the Netherlands. *Ann Surg*. 2017;266:839–46.
7. Takeuchi H, Miyata H, Ozawa S, Udagawa H, Osugi H, Matsubara H, et al. Comparison of short-term outcomes between open and minimally invasive esophagectomy for esophageal cancer using a nationwide database in Japan. *Ann Surg Oncol*. 2017;24:1821–7.
8. Baba Y, Yoshida N, Shigaki H, Iwatsuki M, Miyamoto Y, Sakamoto Y, et al. Prognostic impact of postoperative complications in 502 patients with surgically resected esophageal squamous cell carcinoma: a retrospective single-institution study. *Ann Surg*. 2016;264:305–11.
9. Saeki H, Tsutsumi S, Tajiri H, Yukaya T, Tsutsumi R, Nishimura S, et al. Prognostic significance of postoperative complications after curative resection for patients with esophageal squamous cell carcinoma. *Ann Surg*. 2017;265:527–33.
10. Kataoka K, Takeuchi H, Mizusawa J, Igaki H, Ozawa S, Abe T, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. *Ann Surg*. 2017;265:1152–7.
11. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: a meta-analysis. *Ann Surg*. 2011;254:894–906.
12. Akiyama H, Hiyama M, Miyazono H. Total esophageal reconstruction after extraction of the esophagus. *Ann Surg*. 1975;182:547–52.
13. Bumm R, Hölscher AH, Feussner H, Tachibana M, Bartels H, Siewert JR. Endodissection of the thoracic esophagus. Technique and clinical results in transhiatal esophagectomy. *Ann Surg*. 1993;218:97–104.
14. Tangoku A, Yoshino S, Abe T, Hayashi H, Satou T, Ueno T, et al. Mediastinoscope-assisted transhiatal esophagectomy for esophageal cancer. *Surg Endosc*. 2004;18:383–9.
15. Fujiwara H, Shiozaki A, Konishi H, Komatsu S, Kubota T, Ichikawa D, et al. Hand-assisted laparoscopic transhiatal esophagectomy with a systematic procedure for en bloc infracarinal lymph node dissection. *Dis Esophagus*. 2016;29:131–8.
16. Mori K, Aikou S, Yagi K, Nishida M, Mitsui T, Yamagata Y, et al. Technical details of video-assisted transcervical mediastinal dissection for esophageal cancer and its perioperative outcome. *Ann Gastroenterol Surg*. 2017;1:232–7.
17. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. *Bone Marrow Transplant*. 2013;48:452–8.
18. Brierley JD, Gospodarowicz MK, Wittekind C, editors. *TNM classification of malignant tumors*. 8th ed. Hoboken: Wiley-Blackwell; 2017. pp. 57–62.
19. Japanese Classification of Esophageal Cancer, 11th Edition: part I. *Esophagus*. 2017; **14**: 1–36.
20. Common Terminology Criteria for Adverse Events. (CTCAE) Version 5.0 [Internet]. National Cancer Institute; 2017 [cited 2020 18 May]. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
21. JCOG Clavien-Dindo ver2.0 [Internet]. Japan Clinical Oncology Group; 2018 [cited 2020 18 May]. Available from: http://www.jcog.jp/doctor/tool/JCOG_Clavien-Dindo_ver2.0_CTCAE_ver5.0_20190326.pdf.
22. Mayanagi S, Irino T, Kawakubo H, Kitagawa Y. Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. *Ann Gastroenterol Surg*. 2019;3:269–75.
23. Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N, et al. Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer

in a single institution. *Dis Esophagus*. 2006;19:468–72.

24. Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. *Cancer Sci*. 2013;104:1455–60.
25. Nakamura K, Kato K, Igaki H, Ito Y, Mizusawa J, Ando N, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). *Jpn J Clin Oncol*. 2013;43:752–5.
26. Yamagata Y, Saito K, Hirano K, Oya M. Laparoscopic transhiatal thoracic duct ligation for chylothorax after esophagectomy. *Thorac Cardiovasc Surg*. 2019;67:606–9.

Figures




Figure 1

Location of surgical ports. a. We placed a 4-cm incision on the left neck and inserted a GelPOINT®Mini platform (Applied Medical Co., Ltd, Rancho Santa Margarita, CA, USA), then performed upper to middle mediastinal dissection under inflatable mediastinoscopy. b. We prepared the stomach tube and dissected around the celiac axis using a laparoscope. c. We extended the left cervical incision to the right side, and cervical dissection was performed in direct view.




Figure 2

Mediastinoscopic images after mediastinal dissection. Upper: Complete dissection of the left recurrent laryngeal nerve and the left tracheobronchial lymph nodes (No.106recL and 106tbL, according to the Japanese Classification of Esophageal Cancer). Lower: Complete dissection of the subcarinal and bilateral main bronchus lymph nodes (No. 107 and 109R and 109L, the same as above).




Figure 3

The overall survival (OS) and relapse-free survival (RFS). The median follow-up of the 16 patients was 35.4 months. The 2-year OS was 93.3% (95% CI, 61.3-99.0), and the 3-year OS was 78.8% (95% CI, 47.3-92.7). The 2-year and 3-year RFS were both 73.3% (95% CI, 43.6-89.1). CI, confidence interval